-
Narnatumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)
Quick Facts About NarnatumabWhat is Narnatumab?Narnatumab is a monoclonal antibody targeting CD47, a key immune checkpoint that helps cancer cells evade destruction by the immune system.
CD25 Marker(Post)CD25, a key molecule in immune regulation, is integral to the function of activated lymphocytes and regulatory T cells. It's central in mediating immune responses, with implications in autoimmune
mRNA-1010 and Beyond: How Moderna's mRNA Platform is Revolutionizing Hantavirus Vaccine Development(Post)Hantavirus, a silent threat lurking in rodent populations, has long posed a significant public health challenge with its severe and often fatal outcomes. For decades, the quest for effective vaccines
Guide to Bacterial Transformation: The Science of Genetic Manipulation(Post)Techniques · Molecular CloningGuide to Bacterial Transformation: The Science of Genetic ManipulationBacterial transformation is the process by which bacteria take up foreign DNA — usually a plasmid —
Pathological functions of IL-33/ST2 in IBD and Cancer(Post)By Charlotte O'Donnell PhD < As IL-33/ST2 is such a potent inducer of inflammation, it is not surprising that dysr
CIDE: The New Bioinformatics Engine Unmasking Secreted Proteins for Precision Immunotherapy(Post)For decades, the battle against cancer has focused on the cellular 'soldiers' and the genetic 'blueprints' within them. Yet, a vast, invisible world of communication exists between these cells—a secr
Hydroxychloroquine: Potential Treatment for COVID-19(Post)Hydroxychloroquine: Potential Treatment for COVID-19 What is Hydroxychloroquine? Hydroxychloroquine (HCQ
Atezolizumab: Unveiling the Role of Anti-PD-L1 in Cancer Research(Post)Quick Facts About AtezolizumabWhat is Atezolizumab?Atezolizumab is an anti-PD-L1 monoclonal antibody used in immunotherapy to treat various cancers by enhancing the immune system's abili
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies(Post)Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade(Post)Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
The Complement System - pathways & function in the immune system(Post)The Complement System Function Gone are the days when the complement system was considered solely a companion of its impressive adaptive immune system counte
What Causes Acute Pancreatitis?(Post)Acute pancreatitis (AP) is a condition in which activated enzymes and inflammatory mediators released from the pancreas cause damage to the pancreas and surrounding tissues. AP is furt
Cytokine Release Syndrome and the IL-6 Axis(Page) Dupilumab: Transforming Immunotherapy and Skin Disease Management(Post)What You Need to Know About DupilumabWhat is Dupilumab?Dupilumab is a fully human monoclonal antibody designed to treat various chronic inflammatory diseases by inhibiting key cytokines
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu
Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
Sirexatamab: Advancing CD47-Targeted Cancer Therapy and Research(Post)Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe
OX40 Agonists: Revitalizing the Immune Response in Cancer(Post)Cancer immunotherapy has revolutionized treatment options, offering strategies to harness the immune system to target and destroy tumors. One emerging area of interest is the use of OX40